Notification of HIV status disclosure and its related factors in HIV-infected adolescents in 2009 in the Aconda program (CéPReF, CHU Yopougon) in Abidjan, Côte d'Ivoire, The PRADO-CI Study

Guanga David Meless1, Hortense Aka-Dago-Akribi2, Chantal Cacou2, Tanoh François Eboua3, Addi Edmond Aka4, Aimé Maxime Oga3, Belinda Bouah2, Messou Eugène5, Corinne Moh2, Elise Arrive6,5,6, Marguerite Timité-Konan5 and Valérie Leroy6,5,6 for the PRADO-CI Study Group

Abstract

Introduction: We studied the frequency of documentation of disclosure of HIV status in medical charts and its correlates among HIV-infected adolescents in 2009, in Abidjan, Côte d’Ivoire.

Methods: The PRADO-CI is a cross-sectional study aimed at studying HIV-infected adolescents’ social, psychological, and behavioural difficulties and their determinants in Abidjan, Côte d’Ivoire. In this study, we present specific analyses on disclosure. All HIV-infected adolescents aged 13–21 years and followed at least once in 2009 in two urban HIV-care centres in Abidjan (CéPReF and Yopougon Teaching Hospital) were enrolled in the study. Standardized data were extracted from medical records to document if there was notification of disclosure of HIV status in the medical record. Frequency of notification of HIV disclosure was estimated with its 95% confidence interval (CI) and correlates were analyzed using logistic regression.

Results: In 2009, 229 adolescents were included: 126 (55%) males; 93% on antiretroviral therapy (ART), 61% on cotrimoxazole prophylaxis. Their median age was 15 years at the time of the study. Among the 193 patients for whom information on HIV status disclosure was documented (84%), only 63 (32.6%; 95% CI = 26.0–39.3%) were informed of their status. The proportion of adolescents informed increased significantly with age: 19% for 13–15 years, 33% for 16–18 years and 86% for 19–21 years (p < 0.0001). Adolescents on ART tended to be more likely to be informed of their HIV status (34.5%) than those not treated (13.3%) (p = 0.11). Those on cotrimoxazole were significantly more likely to be informed (39.6%) than those not (21.9%) (p = 0.01). Disclosure was significantly higher in adolescents with a history of ART regimen change (p = 0.003) and in those followed in the CéPReF (48.4%) compared to the Yopougon Teaching Hospital (24.8%), (p = 0.001). In multivariate analyses, disclosed HIV status was significantly higher in those followed-up in the CéPReF compared to the other centre: adjusted odds ratio (aOR) = 3.5 (95% CI: 1.1–10.9), and among older adolescents compared to those aged 13–15 years: [16–18 years aOR = 4.2 (95% CI: 1.5–11.5) and (> 18 years): aOR = 22.1 (95% CI: 5.2–93.5).

Conclusions: HIV disclosure rate was low among Ivorian HIV adolescents and was site- and age-dependent. There is a need for practical interventions to support HIV disclosure to adolescents which provides age-appropriate information about the disease.

Keywords: adolescents and youth; sub-Saharan Africa; antiretroviral treatment; disclosure; HIV; prevention.

Introduction

Worldwide, about 400,000 infants are infected with HIV through mother-to-child transmission (MTCT) annually [1]. These HIV-infected children live longer because of greater access to antiretroviral therapy (ART) and reach adolescence. This is an emerging and growing population with specific features as observed in Africa over the past decade [2,3].

Adolescence is a crucial period of transition to adulthood, characterized by physical, mental, and social changes and challenges. Adolescents starting sexual activity are at high risk of HIV acquisition and transmission in areas of generalized epidemic [4–6]. HIV-infected adolescents face numerous challenges in coping with their disease, with mental health problems, and emotional and behavioural disorders, such as...
anxiety, depression, somatization or suicide attempts [7,8]. Poor virological response to treatment may be associated with non-adherence and sub-optimal antiretroviral use [9]. Adherence to ART is a key issue for therapeutic long-term success. Poor adherence has been reported in both American and South African adolescents [10,11].

Thus, as the number of young HIV-infected people increases, it becomes necessary to develop programmes offering age-appropriate care and treatment, providing psychosocial support, counselling on reproductive health and advocacy on their behalf. Therefore, it is crucial to understand that these problems cannot be adequately addressed in adolescents not informed of their HIV status. In an American context, children and adolescents who knew their HIV status appeared more likely to accept medical care and have a higher self-esteem compared to youth that were unaware of their status [12]. In resource-limited settings, disclosure of HIV status was identified as a factor strongly associated with better adherence [13] and higher retention in care [14].

Therefore, the World Health Organization (WHO) recommends national policies to implement programmes with tools and resources providing clear, specific guidance on disclosure of HIV [15]. However, the process and the resources available for training providers about paediatric HIV disclosure are largely based on the Western disclosure model and experience [16,17] and are often not adapted for low-income countries. In addition, the disclosure process is not well described in sub-Saharan Africa. The prevalence of disclosure in children and adolescents varies according to methods, settings and age of the patients, but is generally low: between 1.7% and 38% in children between five and 17 years in sub-Saharan Africa [6,8,14,18-31]. More specifically, in Zambia, the disclosure rate reached 38% among 127 adolescents aged between 11 and 15 years [8] and was 27% among 96 children at a median age of six years [13]. In Uganda, disclosure of HIV status by caregivers occurred in 29% of 42 children at a median age of 12 years [22]. In Ethiopia, the disclosure rate was only 17% among 390 children with a mean age of 8.5 years [21]. In South Africa, only 9% out of 174 caregivers had disclosed their status to their HIV-children aged 5–17 years [29]. Finally, in Kenya, among 120 children of a mean aged 6.8 years, 1.7% were informed of their HIV status [31].

There are only three studies in west Africa, where HIV prevalence is lower. In Ghana, in a cross-sectional study of 71 caregiver-child pairs, the prevalence of disclosure to their HIV-infected children where children had a median age of 10 years was 21% [27]. Among 650 HIV-infected children aged 10 years or more in Côte d’Ivoire, Mali and Senegal, only 28.8% knew their HIV status [14]. In Nigeria, the caregivers of 96 HIV-infected children of a median age of 8.8 years reported disclosure in only 13.5% of the children [23]. To document what is known by healthcare workers about disclosure of HIV status in routine care, we studied the prevalence and characteristics of HIV disclosure status among HIV-infected adolescents in Abidjan, Côte d’Ivoire.

Methods

Settings

Since 2004, the Aconda antiretroviral programme has offered free care and ART to children in Côte d’Ivoire [33,34]. This programme was funded by the United States President’s Emergency Plan for AIDS Relief (PEPFAR), through the Elizabeth Glaser Paediatric AIDS Foundation (EGPFA; Washington DC, USA) and supported by the French “Groupement d’Intérêt Publique” (GIP) Esther. In Abidjan, the Aconda team trained health workers in HIV care and implemented a standardized computerized data management system in partnership with the Bordeaux School of Public Health (ISPED, France). Overall, in 2009, in the two main Abidjan paediatric centres, 2244 HIV-infected children (0–21 years) were followed in the Aconda active file, of which 1000 were on ART [33].

Paediatric HIV care

The Aconda paediatric HIV care package includes systematic paediatric HIV diagnostic tests. In children over 18 months, the standard serologic testing algorithm was a series of two rapid HIV assays: Determine® HIV-1/2 (Abbott Diagnostics, Abbott Park, IL, USA), followed by Geni II® HIV1/HIV2 (Bio Rad Laboratories, Marne-La-Coquette, France). Children 18 months or older were diagnosed virologically using a TaqMan HIV-1 RNA real-time PCR test with a threshold of 300 copies/mL [35]. Paediatric HIV-1 infection was defined detectable plasma HIV RNA at any age or a HIV-positive serology at age ≥18 months.

All confirmed HIV-infected children attended the programme monthly and had unrestricted and free access to antiretroviral drugs and comprehensive care [36]. Children off and on ART underwent CD4 cell count and CD4 cell percentage measurements every six months. Plasma viral load tests were not routinely available after HIV diagnosis, even in children on ART. Pulmonary X-rays were available for children whose history and symptoms were suggestive of tuberculosis infection. Children initiated ART either at clinical WHO Stage 3 or 4, or at WHO Stage 1 or 2 with impaired immunity defined by age (CD4 count percentage: 25% at <12 months; 20% at 12–18 months; and 15% at ≥36 months) [37]. Cotrimoxazole prophylaxis was given to all HIV-exposed from age six weeks and pursued for all HIV-infected children regardless of their age, as recommended by the national Ivorian guidelines [36].

In each centre, members living with HIV from a community-based women’s organization provided psychological, social and nutritional support, advice on disclosure, and care for adolescents and orphans. Caregivers were informed about this organization and could contact it at their own initiative. The National Ethics Committee of Côte d’Ivoire approved the Aconda data management system [34].

In the four urban centres of the programme offering paediatric care, paediatric and adult care were offered separately in nearby buildings. Beyond the age of 18 years, young people living with HIV were supposed to be transferred to the adult active file, but if they were reluctant, they could remain in follow-up in the paediatric care centre until the age of 21 years. In 2009, there was neither a formal procedure for this transfer from paediatric to adult care nor specific adolescent care.
In 2009, there was no national guideline about the age at disclosure in HIV-infected children in Côte d’Ivoire, where the median age at initiation of sexual activity is 16 years in women and 18 years in men (Health Demographic Survey, 2005). Strategies of HIV disclosure practices varied according to centres. The accepted standard is that disclosure should be done by the age of 13 years, with the intent of disclosure occurring early enough to prevent secondary sexual transmission.

**Study design**
We present data on HIV disclosure in adolescents from the cross-sectional PRADO-CI study conducted in 2009 to explore psychosocial, psychological, behavioural difficulties and their determinants. The PRADO-CI study was nested in the multi-centre prospective paediatric Aconda cohort [33]. All HIV-infected adolescents aged 13–21 years, seen at least once in 2009 in two urban centres (the paediatric ward of the Yopougon Teaching Hospital, and the Centre de Prise en charge de Recherche et de Formation (CePReF)) in Abidjan were eligible for the PRADO-CI study.

**Disclosure process in the study centres**
Clinical personnel in the two study centres had similar practices for conducting disclosure. In the Teaching Hospital, two paediatricians and one psychologist were involved, and in the CePReF, two paediatricians, two psychologists, one social worker and one counsellor were involved. Psychologists provided psychological support to the children and the caregivers, not only for HIV disclosure, but also for adherence to ART. In daily practice, psychologists remind the child’s caregivers that the disclosure process is an important issue, with an increasing need as the child ages, and help them to inform their children themselves. This issue is discussed among the multidisciplinary staffs.

Clinical personnel assessed disclosure status in routine interviews with the child and his/her caregiver. Disclosure status was documented in patients’ charts, although there was not a standardized format for documentation.

**Data collection and analysis**
In each participating paediatric clinic, routine HIV activities were recorded in paper clinical charts and then into an electronic database using unique identification numbers to preserve patient confidentiality.

The following data from patients meeting inclusion criteria were extracted from the paediatric databases:

- Demographic data: date of birth, gender, date of entry in the programme,
- ART regimen: type and date of initiation,
- Cotrimoxazole prophylaxis,
- Clinical condition and CD4 cell count at the time of inclusion.

For the purpose of this study, information in the patient chart regarding adolescent’s knowledge of his/her own HIV status (“Is the adolescent informed about his/her HIV status?”) was collected retrospectively from clinic records from entry into HIV care through 2009 using a standardized data extraction form.

Prevalence of disclosure documented in the clinical chart was estimated with 95% confidence intervals (CIs). To compare the characteristics of adolescents according to sites, as well as of their knowledge of their own HIV status, Fisher and Chi-square tests and Kruskal-Wallis tests were used for qualitative variables and quantitative variables, respectively. Correlates of HIV disclosure were investigated using an adjusted logistic regression including all variables associated with disclosure with a p-value < 0.02 in the univariate analysis. Odds ratio (OR) with 95% CIs were produced. All p-values were two-tailed. A p-value < 0.05 was considered statistically significant. All analyses were performed with SAS software 9.0 (USA).

**Ethics**
The PRADO-CI was funded by Sidaction and approved by the National Ethics Committee of Côte d’Ivoire in April 2009. We requested the IRB approval to collect programme data. For this study, no individual informed consent was requested.

**Results**
Data from May 2009 to April 2010 from 229 adolescents above 13 years of age (10% of the 2244 children on the database) were included in this analysis. The Yopougon clinic had twice as many adolescents as CePReF. The majority 126 (54.6%) were males and 61.4% were on cotrimoxazole prophylaxis (Table 1). The median age was 15 years (range: 13–21 years). The overall age distribution was: 56.8% were aged 13–15 years, 30.6% were 16–18 years and 12.6% were 19–21 years at the time of the study. A quarter was dual-parent orphans, and half had lost at least one parent. These children were in the HIV care programme for a median of 4.3 years and 93% were on ART for a median of 4.8 years. Their median last CD4 cell count at time of the study was 489/mm³ (Table 1).

Data on the adolescents’ knowledge of their own HIV status were missing in 36 cases (15.7%), without significant differences in the baseline variables from those for whom data were available. Among the 193 patients who had data regarding knowledge of HIV status available in the chart (84.3%), only 63 (32.6%, 95% CI = 26.0–39.3%) had been informed of their HIV status, with no significant gender difference (Table 2). The proportion of adolescents informed increased significantly with age: 18.6% for 13–15 years, 33.3% for 16–18 years and 86.2% for 19–21 years (p < 0.0001). Adolescents on ART tended to be more likely to be informed of their HIV status (34.5%) than those not treated (13.3%) (p = 0.11). Those on cotrimoxazole were significantly more likely to be informed of their HIV status (39.6%) than those not receiving cotrimoxazole (21.9%) (p = 0.01). A history of ART regimen change was significantly associated with a higher disclosure rate (p = 0.003). Adolescents were significantly more often informed of their HIV status in the CePReF (48.4%) compared to the Yopougon Teaching Hospital (24.8%) (p = 0.001).

In a fully adjusted model (Table 2), adjusting for centre, gender, age group, history of participation in a research project, ART intake, cotrimoxazole prophylaxis, history of ART regimen change and having no parent, disclosed HIV status was significantly associated with an increased disclosure rate (p = 0.01). Adolescents on ART had a higher disclosure rate than those not treated (OR = 3.9, 95% CI = 1.7–8.9). A history of ART regimen change was associated with a higher disclosure rate (OR = 2.3, 95% CI = 1.1–4.8). Those on cotrimoxazole were more likely to be informed of their HIV status than those not receiving cotrimoxazole (OR = 2.7, 95% CI = 1.2–5.9). A history of ART regimen change was significantly associated with a higher disclosure rate (p = 0.003). Adolescents were significantly more often informed of their HIV status in the CePReF (48.4%) compared to the Yopougon Teaching Hospital (24.8%) (p = 0.001).

status remained significantly higher in adolescents followed-up in the CePReF compared to those in the Yopougon Teaching Hospital: adjusted odds ratio (aOR) = 3.52 (95% CI: 1.1–10.9; p < 0.028); and among older adolescents compared to those aged 13–15 years: [16–18 years] aOR = 4.2 (95% CI: 1.5–11.5; p < 0.005) and [≥ 18 years] vs. [13–15 years]: aOR (22.1; 95% CI: 5.2–93.5; p < 0.0001).

Table 1. Characteristics at study period of all HIV-infected adolescents according to their HIV-care centre (CEPREF and CHU Yopougon) in Abidjan, Côte d’Ivoire, PRADO-CI study, N = 229

| HIV-care centre                      | Overall N = 229 | CEPREF n = 79 | YOPOUGON n = 150 | p       |
|--------------------------------------|----------------|---------------|------------------|---------|
| Gender                               |                |               |                  | 0.279   |
| Female                               | 104 (45.4)     | 32 (40.5)     | 72 (48.0)        |         |
| Male                                 | 125 (54.6)     | 47 (59.5)     | 78 (52.0)        |         |
| Age group (years)                    |                |               |                  | 0.064   |
| [13–15]                              | 130 (56.8)     | 45 (57.0)     | 85 (56.7)        |         |
| [16–18]                              | 70 (30.6)      | 19 (24.0)     | 51 (34.0)        |         |
| > 18                                 | 29 (12.6)      | 15 (19.0)     | 14 (9.3)         |         |
| History of participation in an HIV research project |                |               |                  | 0.0001  |
| Yes                                  | 135 (60.5)     | 30 (40.5)     | 105 (70.5)       |         |
| No                                   | 88 (39.5)      | 44 (59.5)     | 44 (29.5)        |         |
| On ART                               |                |               |                  | 0.172   |
| Yes                                  | 211 (92.9)     | 70 (89.7)     | 141 (94.6)       |         |
| No                                   | 16 (7.1)       | 8 (10.3)      | 8 (5.4)          |         |
| History of ART regimen change        |                |               |                  | 0.491   |
| Yes                                  | 122 (73.1)     | 34 (69.4)     | 88 (74.6)        |         |
| No                                   | 45 (26.9)      | 15 (30.6)     | 30 (25.4)        |         |
| On cotrimoxazole prophylaxis         |                |               |                  | 0.000   |
| Yes                                  | 116 (61.4)     | 40 (90.9)     | 76 (52.4)        |         |
| No                                   | 73 (38.6)      | 4 (9.1)       | 69 (47.6)        |         |
| Treatment                            | Not tested     |               |                  |         |
| None                                 | 3 (1.6)        | 0 (0.0)       | 3 (2.1)          |         |
| Cotrimoxazole                        | 11 (5.8)       | 6 (13.6)      | 5 (3.4)          |         |
| ART                                  | 70 (37.0)      | 4 (9.1)       | 66 (45.5)        |         |
| Cotrimoxazole and ART                | 105 (55.6)     | 34 (77.3)     | 71 (48.0)        |         |
| Father deceased                      |                |               |                  | 0.057   |
| Yes                                  | 99 (48.8)      | 37 (58.7)     | 62 (44.3)        |         |
| No                                   | 104 (51.2)     | 26 (41.3)     | 78 (55.7)        |         |
| Mother deceased                      |                |               |                  | 0.113   |
| Yes                                  | 120 (56.6)     | 45 (64.3)     | 75 (52.3)        |         |
| No                                   | 92 (43.4)      | 25 (35.7)     | 67 (47.7)        |         |
| Orphan of both parents               |                |               |                  | 0.344   |
| Yes                                  | 55 (25.9)      | 21 (30.0)     | 34 (23.9)        |         |
| No                                   | 157 (74.1)     | 49 (70.0)     | 108 (76.1)       |         |
| Knowledge of her/his own HIV status  |                |               |                  | 0.003   |
| Yes                                  | 63 (27.5)      | 31 (39.2)     | 32 (21.3)        |         |
| No                                   | 130 (56.8)     | 33 (41.8)     | 97 (64.7)        |         |
| Missing                              | Median (IQR)   | Median (IQR)  | Median (IQR)     |         |
| Length in HIV care in years (n = 166) | 4.3 [4.0–4.6]  | 4.5 [3.4–4.7] | 4.3 [4.3–4.4]    | 0.249   |
| Length of ART in years (n = 173)     | 4.8 [4.0–6.5]  | 3.9 [2.2–7.1] | 5.0 [4.3–6.4]    | 0.183   |
| Last CD4 cell count in cells/mm³ (n = 221) | 489 [251–679] | 385 [234–673]| 500 [258–680]   | 0.387   |

ART = antiretroviral therapy; IQR = interquartile range.
Discussion

While the disclosure process in adolescents is rarely documented in west Africa, our study provided an opportunity to document the proportion of HIV-infected adolescents informed of their HIV status as known by the healthcare staff in an Ivorian routine HIV-care context. The reported disclosure rate was low, reaching only 32.6% of the HIV-infected adolescents. In an adjusted model of the correlates of disclosure, this proportion increased significantly with age, with 86.2% of those aged from 19 to 21 years having had disclosure of their status and differed significantly according to the clinical centres.

There are several limitations to our observations. First, the completeness of the data analyzed, collected during outpatient routine follow-up and reported in medical records, might have been the source of bias; we hypothesized that it could have led to an underestimation of the disclosure rate. We observed significantly higher frequency of disclosure notifications in the CePREF centre compared to the Yopougon Teaching Hospital. The CePREF centre had a strong track record in research, had more trained personnel and a smaller adolescent population. The absence of procedures or standardized forms to document HIV disclosure in the medical record may have contributed to a probable underestimation and also to missing data. Second, our study was nested in a cross-sectional study and our documentation was based on a cumulative rate of notification of disclosure, not taking into account the dynamic evolution of the disclosure process. A retrospective qualitative analysis of the history of the disclosure process could allow a deeper exploration of the accuracy and the evolution of the disclosure process; however, this information will remain limited by memory bias. A prospective cohort to document this dynamic process of disclosure would be desirable. Nevertheless, the disclosure rate from this study may be useful as a baseline reference for HIV-infected adolescents in West Africa.

There are few studies about disclosure to adolescents of their HIV status in west Africa to compare our findings to

### Table 2. Characteristics at study period associated with the notification of the disclosure of their own HIV status in adolescents in Abidjan, Côte d’Ivoire

| Notification of disclosure in adolescents | Univariate model | Adjusted model |
|------------------------------------------|------------------|----------------|
| **Centre**                               |                  |                |
| CEPREF                                   | 31 (48.4)        | 2.84 [1.51–5.36] | 3.52 [1.15–10.85] | 0.028 |
| CHU Yopougon                              | 32 (24.8)        | 1              |                |
| **Gender**                               |                  |                |
| Female                                   | 25 (30.9)        | 0.87 [0.47–1.60] | 1.36 [0.53–3.48] | 0.523 |
| Male                                     | 38 (33.9)        | 1              |                |
| **Age group (years)**                    |                  |                |
| [13–15]                                  | 21 (18.6)        | 1              |               |
| [16–18]                                  | 17 (33.3)        | 2.19 [1.03–4.6] | 4.21 [1.54–11.49] |                |
| > 18                                     | 25 (86.2)        | 27.38 [8.61–87.08] | 22.08 [5.22–93.49] |                |
| **History of participation in a research project** |                  |                |
| Yes                                      | 44 (37.9)        | 2.05 [1.06–3.96] | 1.93 [0.61–6.08] | 0.259 |
| No                                       | 17 (23.0)        | 1              |                |
| **On ART**                               |                  |                |
| Yes                                      | 61 (34.5)        | 3.42 [0.75–15.63] | 1.15 [0.09–15.21] | 0.914 |
| No                                       | 2 (13.3)         | 1              |                |
| **On cotrimoxazole prophylaxis**          |                  |                |
| Yes                                      | 40 (39.6)        | 2.34 [1.15–4.78] | 2.04 [0.77–5.41] | 0.152 |
| No                                       | 14 (21.9)        | 1              |                |
| **History of ART regimen change**         |                  |                |
| Yes                                      | 46 (42.2)        | 4.13 [1.60–10.67] | 3.83 [0.92–15.92] | 0.065 |
| No                                       | 6 (15.0)         | 1              |                |
| **Orphan of both parents**                |                  |                |
| Yes                                      | 14 (29.2)        | 0.87 [0.61–1.24] | 0.28 [0.09–0.88] | 0.290 |
| No                                       | 47 (35.3)        | 1              |                |

ART = antiretroviral therapy; OR = odds ratio; CI = confidence interval. Univariate and adjusted logistic regression. PRADO-CI study, N = 193.
Disclosure rate was low among Ivoirian HIV adolescents and provides age-appropriate information about the disease.

Conclusions

Disclosure rate was low among Ivorian HIV adolescents and site- and age-dependent. There is a need for development of practical interventions to support HIV disclosure to adolescents and provide age-appropriate information about the disease.

Acknowledgements

The authors acknowledge all of the children and families followed up in the participating paediatric centres. We acknowledge Karen Malaste (IPED) for her data management support. The Aconda program was funded by the United States President’s Emergency Plan for AIDS Relief (PEPFAR), through the Elizabeth Glaser Paediatric AIDS Foundation (EGPAF, Washington, DC, USA), with additional support from the French GIP ESTHER and the Côte d’Ivoire Ministry of Public Health. The authors give special thanks to Sophie Desmonde for her helpful reading. We warmly thank Sidaction-Ensemble contre le Sida and Thomas Munyizangabo, HIV/AIDS and Adolescents Programme, UNICEF Côte d’Ivoire, for their funding support for the PRADO-CI Study.

Sources of funding

The PRACO-CI study was funded by SIDACTION, Ensemble contre le Sida UNICEF, Abidjan, Côte d’Ivoire. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of any of these institutions. The funders had no role in study design, data collection and analysis, decision to publish or preparation of this article.

References

1. UNAIDS. UNAIDS World AIDS day report 2011. How to get to zero faster, smarter, better. Geneva: UNAIDS; 2011.
2. Foster C, Waebroock A, Pelletier A. Adolescents and HIV infection. Curr Opin HIV AIDS. 2007;2(5):431–6.
3. Foster C, Fider S. Optimizing antiretroviral therapy in adolescents with perinatally acquired HIV-1 infection. Expert Rev Anti-Infect Ther. 2010;8(12):1403–16.
4. UNAIDS. UNAIDS Report on the global AIDS epidemic. Geneva: UNAIDS; 2010.
5. Wilson C, Wright P, Saffit J, Rudy B. Epidemiology of HIV infection and risk in adolescents and youth. J Acquir Immune Defic Syndr. 2010;54(Suppl 1):S5–6.
6. Gray GE. Adolescent HIV—cause for concern in Southern Africa. PLoS Med. 2010;7(2):e1000227.
7. Musisi S, Kinyanda E. Emotional and behavioural disorders in HIV seropositive adolescents in urban Uganda. East Afr Med J. 2009;86(1):16–24.
8. Menon A, Glazebrook C, Campain N, Ngoma M. Mental health and disclosure of HIV status in Zambian adolescents with HIV infection: implications for peer-support programs. J Acquir Immune Defic Syndr. 2007;46(3):349–54.
9. Ding H, Wilson CM, Modjarrad K, McGwin G, Jr., Tang J, Vermund SH. Predictors of suboptimal virologic response to highly active antiretroviral therapy among human immunodeficiency virus-infected adolescents: analyses of the reaching for excellence in adolescent care and health (REACH) project. Arch Pediatr Adolesc Med. 2009;163(12):1100–5.
10. Rudy BJ, Crowley-Novick PA, Douglas SD. Immunology and the REACH study: HIV immunology and preliminary findings. Reaching for Excellence in Adolescent Care and Health. J Adolesc Health. 2001;29(Suppl 3):39–48.
11. Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, Regensberg L, et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr. 2009;53(1):65–71.
12. Gerson AC, Joyner M, Fosarelli P, Butz A, Wissow L, Lee S, et al. Disclosure of HIV diagnosis to children: when, where, why, and how. J Pediatr Health Care. 2001;15(4):161–7.
13. Haberer JE, Cook A, Walker AS, Ngambiri M, Ferrier A, Mulenga V, et al. Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects. PLoS One. 2011;6(4):e18505.
14. Arrive E, Dicko F, Anghar A, Aka AE, Dior H, Bouah B, et al. HIV status disclosure and retention in care in HIV-infected adolescents on antiretroviral therapy (ART) in West Africa. PLoS One. 2012;7(3):e33690.
15. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach. Revision 2010. Geneva: WHO; 2010.
16. ANECCA, [African network for the care of children affected by HIV/AIDS HoPAA]. Réseau Africain pour les soins aux enfants affectes par le SIDA. Manuel sur le SIDA pédiatrique en Afrique Edition Révisée, Juillet 2006. Oxford, UK: Blackwell Science; 2006.
17. World Health Organization. Guideline on HIV disclosure counselling for children up to 12 years of age. Geneva: WHO; 2011.
18. Abbee W, Teferra S. Disclosure of diagnosis by parents and caregivers to children infected with HIV: prevalence associated factors and perceived barriers in Addis Ababa, Ethiopia. AIDS Care. 2012;24(9):1097–102.
19. Arun S, Singh AK, Lodha R, Kabra SK. Disclosure of the HIV infection status in children. Indian J Pediatr. 2009;76(8):805–8.
20. Bhattacharya M, Dubey AP, Sharma M. Patterns of diagnosis disclosure and its correlates in HIV-infected North Indian children. J Trop Pediatr. 2011;57(6):405–11.
21. Biazglign S, Deribew A, Amberbir A, Escudero HR, Deribe K. Factors associated with HIV/AIDS diagnostic disclosure to HIV infected children receiving HAART: a multi-center study in Addis Ababa, Ethiopia. PLoS One. 2011;6(3):e17572.
22. Bikaako-Kajara W, Luyirika E, Purcell DW, Downing J, Kaharuza F, Mermin J, et al. Disclosure of HIV status and adherence to daily drug regimens among HIV-infected children in Uganda. AIDS Behav. 2006;10(Suppl 4):S85–93.
23. Brown BJ, Gidakokun RE, Osinuai K, Ochigbo S, Adewole IF, Kanki P. Disclosure of HIV/AIDS status to infected children in a Nigerian HIV Care Programme. AIDS Care. 2011;23(9):1053–8.
24. Calabrese SK, Martin S, Wolters PT, Toledo-Tamala MA, Brennan TL, Wood LV. Diagnosis disclosure, medication hiding, and medical functioning among perinatally infected, HIV-positive children and adolescents. AIDS Care. 2012;24(9):1092–6.
25. De Baets AJ, Siyovo S, Parsons R, Pazzakavambwa IE. HIV disclosure and discussions about grief with Shona children: a comparison between health workers and community members in Eastern Zimbabwe. Soc Sci Med. 2006;66(6):1479–81.
26. Heeren GA, Jemmott JB, 3rd, Sidlory L, Ngwane Z. Disclosure of HIV infection to HIV-infected children in South Africa: focus groups for intervention development. Vulnerable Child Youth Stud. 2012;7(1):47–54.
27. Kallem S, Renner L, Ghrebremichael M, Paintsil E. Prevalence and pattern of disclosure of HIV status to HIV-infected children in Ghana. AIDS Behav. 2011;15(6):1121–7.
28. Obderforer F, Puthanakit T, Louthereo O, Charnsil C, Srisantha V, Srisantha T. Disclosure of HIV/AIDS diagnosis to HIV-infected children in Thailand. J Paediatr Child Health. 2006;42(5):283–8.
29. Vaz LM, Maman S, Eng E, Barbarin OA, Thikudan T, Behets F. Patterns of disclosure of HIV status to infected children in a Sub-Saharan African setting. J Dev Behav Pediatr. 2011. [Epub ahead of print].
30. Bakanda C, Birungi J, Nyenga R, Nachega J, Chan K, Palmer A, et al. Survival of HIV-infected adolescents on antiretroviral therapy in Uganda: findings from a nationally representative cohort in Uganda. PLoS One. 2011;6(4):e19261.
31. Vreeman RC, Nyandiok WM, Ayya SO, Walumbe EG, Marrero DG, Inui TS. The perceived impact of disclosure of pediatric HIV status on pediatric antiretroviral therapy adherence, child well-being, and social relationships in a resource-limited setting. AIDS Patient Care STDs. 2010;24(10):639–49.
32. Moodley K, Myer L, Michaels D, Cotton M. Paediatric HIV disclosure in South Africa – caregivers’ perspectives on discussing HIV with infected children. S Afr Med J. 2006;96(3):201–4.
33. Anany MF, Duvignac J, Wemim L, Kouakoussui A, Kancher S, Toure S, et al. Scaling up antiretroviral therapy for HIV-infected children in Côte d’Ivoire: determinants of survival and loss to programme. Bull World Health Organ. 2010;88(7):490–9.
34. Toure S, Kouadio B, Seyler C, Traore M, Dalkouy-Dogbo N, Duvignac J, et al. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d’Ivoire: two-year outcomes and determinants. AIDS. 2008;22:873–82.
35. Rouet F, Elouevi DK, Chaix ML, Burgard M, Inwoley A, Tony TD, et al. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol. 2005;43(6):2709–17.
36. République de Côte d’Ivoire. Guide de prise en charge pédiatrique de l’infection par le VIH en Côte d’Ivoire [Guide on pediatric care of HIV in Côte d’Ivoire]. Abidjan: Ministère de la Santé et de l’Hygiène Publique. Ministère de la Lutte contre le SIDA; 2006. 156 p.
37. World Health Organization. WHO HIV prevention and treatment guidelines. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings, towards universal access: recommendations for a public health approach (2006 version). Geneva: WHO; 2006.
38. Foster SD, Nakamanya S, Kyomuhangi R, Amuroro J, Namara G, Amuron B, et al. The experience of “medicine companions” to support adherence to antiretroviral therapy: quantitative and qualitative data from a trial population in Uganda. AIDS Care. 2010;22(Suppl 1):35–43.
39. Michaud PA, Suris JC, Thomas LR, Kahler C, Rudin C, Cheseaux JL. To say or not to say: a qualitative study on the disclosure of their condition by human immunodeficiency virus-positive adolescents. J Adolesc Health. 2009;44(4):356–62.
40. Rujumba J, Mbasaalaki-Mwaka CL, Ndeezi G. Challenges faced by health workers in providing counselling services to HIV-positive children in Uganda: a descriptive study. J Int AIDS Soc. 2010;13:9.